跳至主要内容
临床试验/NCT00420615
NCT00420615已完成1 期

An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
34
试验地点
1
主要终点
To evaluate the effects of patupilone on the pharmacokinetics of omeprazole in patients with advanced malignancies

研究概览

简要总结

The purpose of this study is to evaluate the potential inhibitory effects of patupilone on metabolism using midazolam and omeprazole as the respective probe drugs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Patupilone and Omeprazole

Experimental

patupiloe + omeprazole

干预措施: Patupilone and Omeprazole (Drug)

patupilone + midalzolam

Experimental

patupilone + midalzolam

干预措施: Patupilone + Midalzolam (Drug)

结局指标

主要结局

To evaluate the effects of patupilone on the pharmacokinetics of omeprazole in patients with advanced malignancies

时间窗: Day 1 (0.33h (20m), 0.67h (40m), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h)

To evaluate the effects of patupilone on the pharmacokinetics of midazolam in patients with advanced malignancies.

时间窗: Day 1 (0.5h, 1h, 1.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h), Day 29 (0.5h, 1h, 1.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h)

次要结局

  • To evaluate the safety and tolerability of Patupilone when administered concomitantly with omeprazole in patients with advanced malignancies.(at each visit (week 1, week 2, week 5, and end of study))
  • To evaluate the safety and tolerability of Patupilone when administered concomitantly with midazolam in patients with advanced malignancies.(at each visit (week 1, week 2, week 5, and end of study))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验